Transdermal Prodrug Patch for Acetaminophen and Ibuprofen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively addressed the challenge of delivering anti-pyretic, analgesic, and anti-inflammatory drugs through transdermal routes due to the physicochemical properties of drugs like acetaminophen and ibuprofen, which are not suited for such applications.
Innovation Solution
The development of a transdermal drug delivery system comprising an adhesive polymer matrix layer; and at least one stable NSAID or analgesic prodrug dispersed within the polymer matrix layer, which includes a backing layer, a release liner, and a rate-controlling polymeric membrane.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If transdermal delivery is attempted for acetaminophen and ibuprofen, then alternative route of administration is achieved, but the drugs are not well-suited for transdermal delivery due to physicochemical properties
Solution Approach 1:
The patent modifies the physicochemical parameters of acetaminophen and ibuprofen by converting them into prodrug formulations with altered molecular structures. This changes their lipophilicity and other properties to make them suitable for transdermal delivery, resolving the contradiction between achieving alternative administration routes and maintaining delivery effectiveness.
Solution Approach 2:
The patent introduces prodrugs as intermediary compounds that serve as carriers for the active drugs. These prodrugs facilitate transdermal penetration by mediating between the skin barrier and the active pharmaceutical ingredients, enabling effective delivery that would not be possible with the parent drugs alone.
2Reliability
If prodrugs are used to improve transdermal delivery, then physicochemical properties are enhanced, but drug stability must be maintained
Solution Approach 1:
The patent carefully selects and modifies chemical parameters of the prodrugs to achieve the right balance between stability and deliverability. By controlling the chemical structure, molecular weight, and other parameters, the prodrugs remain stable during storage while enabling effective transdermal delivery upon application.
3Object-affected harmful factors
If transdermal delivery system is developed, then gastrointestinal absorption problems are avoided, but device complexity increases
Solution Approach 1:
The patent divides the transdermal delivery system into distinct functional segments: prodrug formulation layer, penetration enhancement layer, and active drug release layer. This segmentation allows each component to address specific challenges while keeping the overall system manageable and not excessively complex.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a stable and effective delivery of acetaminophen and ibuprofen, which addresses the challenge of delivering acetaminophen and ibuprofen, which are not particularly well-suited for transdermal delivery, achieving improved physicochemical and pharmacokinetic features, and enhancing patient compliance.
Implementation Method 1
the prodrug diffuses through the skin or mucosa of the subject to achieve desired therapeutic systemic levels of the analgesic or NSAID
Implementation Method 2
an adhesive polymer matrix layer
Data Source
AI summary
The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.